טוען...
Inhibition of γ-Secretase Leads to an Increase in Presenilin-1
γ-Secretase inhibitors (GSIs) are potential therapeutic agents for Alzheimer’s disease (AD); however, trials have proven disappointing. We addressed the possibility that γ-secretase inhibition can provoke a rebound effect, elevating the levels of the catalytic γ-secretase subunit, presenilin-1 (PS1)...
שמור ב:
| הוצא לאור ב: | Mol Neurobiol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5948247/ https://ncbi.nlm.nih.gov/pubmed/28815510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12035-017-0705-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|